Our study also found that MAPK signaling pathway was closely related to osimertinib resistance of NSCLC, and RPS6KA1, CACNA1B and MAPK8IP3 were significantly enriched in “MAPK signaling pathway” (Table 3). The gene discussed is CACNA1B; the disease is non-small cell lung carcinoma.